Pupillary Pathways

Follow Us

Talin Amadian

Dr. Talin Amadian is a practicing optometrist, writer and content contributor for Optoprep. She graduated from Western University of Health Sciences College of Optometry and continues to practice in Southern California. Her clinical training includes Neuro-Ophthalmology, Cornea and Refractive Surgery, Glaucoma and Ocular Disease. Dr. Amadian takes pride in educating patients and providing specialized care and education based on each patient’s needs. She is passionate about dry eye treatment and management. During her spare time, she enjoys mentoring and helping prospective optometry students succeed.

Recent Posts

What Every Optometry Student Needs to Know about Miotics and Combination Drugs

Posted by Talin Amadian on September 29, 2020 at 11:37 AM
Read More

Topics: Miotics, Combination Drugs

What I Learned About CAIs/Alpha-2 Agonists That Will Help Any Optometry Student

Posted by Talin Amadian on September 22, 2020 at 12:30 PM

In the last blog post, we covered first-line glaucoma medications, Prostaglandin analogs, and Beta-blockers. Besides these key players, there are a few more categories of glaucoma medications that surely deserve recognition. Let’s review alpha-2 agonists and carbonic anhydrase inhibitors!

Read More

Topics: Agonists, CAI's, Alpha-2

Everything You Need to Know about Prostaglandin Analogs & Beta-Blockers

Posted by Talin Amadian on September 12, 2020 at 8:54 AM

So you’ve completed your entire Glaucoma workup, what’s next? The hardest part about prescribing glaucoma medications is figuring out where to start. With so many drugs available on the market, it can become very overwhelming, especially when you are in a time crunch in between patients.

Though each patient has a different clinical presentation, overall knowledge of the various Glaucoma drug categories and their mechanism-of-action will guide you through this process. 

Here’s a refresher of the two most common first-line glaucoma drugs!

Read More

Topics: Analogs, Beta-Blockers

New call-to-action

 

Subscribe to Our Blog

New call-to-action

 

Popular Posts

Posts by Topic

see all

New Call-to-action